1212 The Lack of Tolerable Treatment Options That Can Induce Durable Responses without Fear of Relapse after Discontinuation Represents a Significant Unmet Need for Patients (Pts) with Immune Thrombocytopenia (ITP): Results from the ITP World Impact Survey (I-WISh) 2.0.
This was the video presentation for the above names abstract from ASH 2023.
James B. Bussel, MD1, Nichola Cooper, MD2*, Waleed Ghanima, MD, PhD3,4, Drew Provan5*, Yoshiaki Tomiyama, MD, PhD6, Ming Hou7*, Donald Arnold, MD8, Cristina Santoro9*, Francesco Zaja, MD10*, Barbara Lovrencic11*, Mervyn Morgan12*, Leron Lahav13*, Michal Winograd13*, Jennifer MacWhirter - DiRaimo14*, Tom Bailey15*, Moyra Aziz16*, Roberto Abi Rached16* and Caroline Kruse17*
1Weill Cornell Medicine, New York, NY
2Department of Inflammation and Immunity, Imperial College London, London, United Kingdom
3Østfold Hospital Trust, Kalnes, Norway
4University of Oslo, Oslo, Norway
5Barts and The School of Medicine and Dentistry, London, United Kingdom
6Osaka University Hospital, Osaka, Japan
7Qilu Hospital of Shandong University, Shandong, China
8McMaster University, Hamilton, ON, Canada
9University Hospital Policlinico Umberto I, Rome, Italy
10DSM, University of Trieste and Department of Hematology, Azienda Sanitaria Universitaria Giuliano-Isontina, Trieste, Italy
11AIPIT aps - Italian Association of Immune Thrombocytopenic Purpura, Caprino, Veronese, Italy
12ITP Support Association, Bolnhurst, United Kingdom
13ITP Israel, the Israeli association of ITP, Ramat Hasharon, Israel
14Platelet Disorder Support Association, Ontario, Canada
15Adelphi Real World, Bollington, United Kingdom
16Novartis Pharma AG, Basel, Switzerland
17Platelet Disorder Support Association, Cleveland, OH
16 сен 2024
